How PBI/Gordon Companies leveraged our Sirolimus API Market report
VM Intelligence · Sample preview · Healthcare and Pharmaceuticals · Forecast 2027–2033
Down Syndrome Diagnosis and Treatment Market
- By Diagnosis Method: Non-Invasive Prenatal Testing (NIPT), Chorionic Villus Sampling (CVS), Amniocentesis, Ultrasound Screening, Maternal Serum Screening
- By Treatment Type: Early Intervention Programs, Speech Therapy, Physical Therapy, Occupational Therapy, Behavioral Therapy, Pharmacological Treatment
- By End User: Hospitals, Diagnostic Laboratories, Specialty Clinics, Home Healthcare Providers, Rehabilitation Centers
- By Technology: Molecular Diagnostics, Imaging Technology, Genetic Testing Platforms, Biochemical Assays, Telehealth Solutions
Key Highlights
A snapshot of what the full report proves- 01 Market size - $X,XXX.XM global market in 2025 - the verified base-year revenue. Executive Summary →
- 02 Forecast - Full 2033 market projection modelled inside - unlock the forecast value to see where the market lands. Market Outlook →
- 03 Growth - Year-by-year CAGR across 2027–2033 - unlock the growth rate and the full model. Market Outlook →
- 04 Leading segment - Non-Invasive Prenatal Testing (NIPT) leads By Diagnosis Method at XX% share. Market, by Service Type →
- 05 Global coverage - Sized across 5 regions and 20 countries, each broken out by segment. Market, by Geography →
- 06 Competitive landscape - 16 companies profiled with SWOT, benchmarking and market-share analysis. Company Profiles →
Inside the Report
11 chapters · 286 pages- 01 Introduction Definition, segmentation & scope p.12 →
- 02 Research Methodology How the numbers were built p.20 →
- 03 Executive Summary The market in one chapter p.34 →
- 04 Market Outlook Drivers, restraints, trends p.63 →
- 10 Competitive Landscape 5 sections p.171 →
- 11 Company Profiles 16 players: SWOT & benchmarking p.179 →
Full report · locked preview
Everything inside the Down Syndrome Diagnosis and Treatment Market report
A complete, evidence-based study - 11 chapters and 120 sections covering market size, segmentation across 4 axes, regional analysis and 16 company profiles, forecast to 2033.
Segmentation covered
Companies profiled
★★★★★ Excellent
16 players profiled - tiered by revenue contribution, footprint and R&D capability.
ACE Matrix · p.153 →Roche Diagnostics
Tier 1 · Market Leader
SWOT · Benchmarking · Winning imperatives · Strategies
Full profile · p.155 →Abbott Laboratories
Tier 1 · Market Leader
SWOT · Benchmarking · Winning imperatives · Strategies · Key developments
Full profile · p.160 →Illumina Inc.
Tier 1 · Market Leader
SWOT · Benchmarking · Winning imperatives · Strategies
Full profile · p.166 →Thermo Fisher Scientific
Tier 1 · Market Leader
SWOT · Benchmarking · Winning imperatives · Strategies · Key developments
Full profile · p.173 →PerkinElmer Inc.
Tier 1 · Market Leader
SWOT · Benchmarking · Winning imperatives · Strategies
Full profile · p.178 →Agilent Technologies
Tier 1 · Market Leader
SWOT · Benchmarking · Winning imperatives · Strategies · Key developments
Full profile · p.184 →Bio-Rad Laboratories
Tier 1 · Market Leader
SWOT · Benchmarking · Winning imperatives · Strategies
Full profile · p.191 →Natera Inc.
Tier 2 · Established Specialist
Overview · Insights · Product benchmarking
Full profile · p.196 →Becton
Tier 2 · Established Specialist
Overview · Insights · Product benchmarking
Full profile · p.202 →Dickinson and Company (BD)
Tier 2 · Established Specialist
Overview · Insights · Product benchmarking · Segment breakdown
Full profile · p.209 →F. Hoffmann-La Roche AG
Tier 2 · Established Specialist
Overview · Insights · Product benchmarking
Full profile · p.214 →Myriad Genetics Inc.
Tier 2 · Established Specialist
Overview · Insights · Product benchmarking
Full profile · p.220 →Quest Diagnostics Incorporated
Tier 3 · Niche Player
Overview · Insights · Product benchmarking
Full profile · p.227 →Invitae Corporation
Tier 3 · Niche Player
Overview · Insights · Product benchmarking
Full profile · p.232 →Genomic Health Inc.
Tier 3 · Niche Player
Overview · Insights · Product benchmarking
Full profile · p.238 →Sema4
Tier 3 · Niche Player
Overview · Insights · Product benchmarking
Full profile · p.245 →Market estimates & forecast (USD Million)
Fig. 15 · p.34 →Segment mix, 2033 (% share)
Fig. 16 · p.35 →- Non-Invasive Prenatal Testing (NIPT)40.5
- Chorionic Villus Sampling (CVS)19.4
- Amniocentesis18.2
- Ultrasound Screening11.0
- Maternal Serum Screening10.9
Regions, 2025 → 2033 (USD Mn)
§6.1 · p.75 →Top countries, 2033 (USD Mn)
§6.2 · p.78 →Year-over-year growth (%)
§3.12 · p.44 →CAGR by region (%)
Fig. 22 · p.71 →Market share by company, 2033 (%)
Fig. 41 · p.152 →- Roche Diagnostics16.5
- Abbott Laboratories14.4
- Illumina Inc.12.4
- Thermo Fisher Scientific13.8
- PerkinElmer Inc.7.4
- Agilent Technologies7.4
- Others28.1
Segment contribution to growth (%)
Fig. 18 · p.39 →Competitive positioning (ACE matrix)
Fig. 40 · p.153 →Adoption & penetration (% of addressable)
Fig. 12 · p.31 →Revenue by application (USD Mn)
§5.3 · p.62 →Demand by end-use (USD Mn)
§5.4 · p.66 →Average selling price trend (index, 2025=100)
Fig. 27 · p.58 →Top companies by revenue, 2033 (USD Mn)
Fig. 42 · p.155 →Revenue by region, 2033 (%)
Fig. 20 · p.70 →- North America32.9
- Europe21.8
- Asia Pacific22.3
- Latin America13.7
- Middle East and Africa9.3
8 players benchmarked across 6 dimensions — scored 0–100 from share, portfolio, reach, innovation, financials and installed base. Methodology · §8.1 · p.160 →
Competitive scorecard (score 0–100)
Table 31 · p.161 →| Company | Market share | Product portfolio | Geographic reach | Innovation & R&D | Financial strength | Customer base | Composite |
|---|---|---|---|---|---|---|---|
| Roche Diagnostics | 86 | 85 | 75 | 99 | 79 | 74 | 83 |
| Abbott Laboratories | 84 | 74 | 76 | 90 | 90 | 93 | 85 |
| Illumina Inc. | 67 | 71 | 69 | 81 | 84 | 84 | 76 |
| Thermo Fisher Scientific | 69 | 73 | 82 | 68 | 67 | 74 | 72 |
| PerkinElmer Inc. | 51 | 71 | 62 | 66 | 55 | 53 | 60 |
| Agilent Technologies | 47 | 70 | 68 | 60 | 63 | 61 | 62 |
| Bio-Rad Laboratories | 63 | 54 | 65 | 59 | 52 | 58 | 59 |
| Natera Inc. | 47 | 52 | 45 | 44 | 43 | 41 | 45 |
Vendor positioning (presence × innovation)
Fig. 43 · p.163 →Strengths profile (top 3 players)
Fig. 44 · p.165 →- Roche Diagnostics
- Abbott Laboratories
- Illumina Inc.
Capability coverage
§8.3 · p.168 →| Company | Global delivery | R&D depth | Digital platform | Sustainability | After-sales | Custom solutions |
|---|---|---|---|---|---|---|
| Roche Diagnostics | ◐ | ✓ | ◐ | ✓ | ✓ | ◐ |
| Abbott Laboratories | ✓ | ✓ | ✓ | ✓ | ✓ | ◐ |
| Illumina Inc. | ◐ | ◐ | − | ✓ | ◐ | ✓ |
| Thermo Fisher Scientific | ◐ | ◐ | ◐ | ◐ | ◐ | ◐ |
| PerkinElmer Inc. | ◐ | ◐ | ◐ | ◐ | − | ◐ |
| Agilent Technologies | − | ◐ | ✓ | − | ◐ | ◐ |
| Bio-Rad Laboratories | ◐ | ◐ | ◐ | ◐ | − | ◐ |
| Natera Inc. | − | − | − | − | − | − |
✓ Full ◐ Partial − Limited
Overall competitive index (composite, ranked)
Fig. 45 · p.170 →Competitive tiers
§8.4 · p.172 →Leader2
Set the pace on share, breadth and innovation.
Challenger2
Strong scale, closing on the leaders.
Contender3
Focused players with pockets of strength.
Niche1
Specialists in a single segment or region.
Go-to-market strategy
Land Diagnosis Method in North America, then scale across Down Syndrome Diagnosis and Treatment Market — a $554M beachhead inside a $9.05B market.
Ideal customer profile (who to sell to)
§GTM 1 · p.190 →Non-Invasive Prenatal Testing (NIPT)
Best fit — highest urgency & budget in Diagnosis Method.
Chorionic Villus Sampling (CVS)
Strong fit — clear ROI and a fast path to value.
Amniocentesis
Emerging fit — growing demand, longer sales cycle.
Market-entry sequence (beachhead → scale)
Fig. GTM 1 · p.192 →Beachhead · 2025–2026
Win Diagnosis Method in North America
Concentrated ICP, fastest proof and references.
Expand · 2026–2028
Add Treatment Type & next regions
Repeat the motion in adjacent, look-alike segments.
Scale · 2028–2033
Full-market coverage + End User
Multi-channel, platform & ecosystem plays.
Channel mix (routes to market)
§GTM 3 · p.195 →Positioning & messaging
§GTM 2 · p.194 →For Diagnosis Method leaders who need defensible market intelligence, VM Intelligence is the fastest, source-cited way to size, segment and win Down Syndrome Diagnosis and Treatment Market — unlike generic, static research.
Live & source-cited
Every figure triangulated from 600K+ sources and traceable.
Ready in minutes
A full, tailored report compiled on demand — not weeks.
Scope you control
Pick the chapters, regions and companies that matter.
GTM funnel & unit economics (conversion · CAC / LTV)
Fig. GTM 2 · p.198 →Investment thesis
Down Syndrome Diagnosis and Treatment Market is a high-growth opportunity — $9.93B by 2033, compounding at 11.7%.
Market opportunity (TAM · SAM · SOM)
Fig. 3 · p.14 →Growth trajectory (USD Million)
Fig. 4 · p.16 →Why invest now
§2.1 · p.10 →11.7% CAGR
Demand compounds through 2033, outpacing GDP across Diagnosis Method.
Global tailwinds
North America leads today; fastest gains coming from emerging regions.
Structural shift
Adoption in Diagnosis Method moving from early to mainstream — durable secular demand.
Consolidation upside
16+ players, no runaway leader — room to build scale and roll up share.
Investment highlights
§2.2 · p.12 →Return scenarios (2033 market value)
Fig. 6 · p.22 →Key risks & mitigants
§9.1 · p.180 →- Input-cost volatilityLong-term supply contracts & hedging
- Regulatory / policy shiftsDiversified exposure across 5 regions
- Technology disruptionR&D pipeline & Treatment Type optionality
- Customer concentrationBroaden installed base beyond top accounts
Board pack · executive summary
Down Syndrome Diagnosis and Treatment Market — a $2.13B market by 2033. Plan: grow share from 10.8% to 17.5%.
Strategic scorecard (current vs 2033 target)
Table 1 · p.6 →| Objective | Current | Target · 2033 | Status |
|---|---|---|---|
| Market share | 10.8% | 17.5% | On track |
| Revenue | $224M | $372M | On track |
| Geographic coverage | 2 of 5 regions | 5 of 5 regions | On track |
| Segment coverage | 2 of 4 axes | 4 of 4 axes | At risk |
| Gross margin | 34.9% | 39.1% | At risk |
| Customer retention | 91.0% | 93.0% | On track |
Where to play (strategic priorities)
§1.2 · p.8 →Lead segment
Win in Diagnosis Method
Largest revenue pool and fastest secular demand — concentrate to build share here first.
Geographic
Expand across North America & beyond
Deepen the leading region, then scale into the fastest-growing emerging markets.
Adjacency
Build Treatment Type capability
A defensible second engine — invest in Treatment Type to widen the moat and cross-sell.
Strategic roadmap (2025–2033)
Fig. 1 · p.10 →Phase 1 · Foundation
2025–2027
- Secure core Diagnosis Method share
- Fix unit economics
- Stand up data & ops
Phase 2 · Scale
2028–2030
- Enter new regions
- Launch Treatment Type
- Selective M&A
Phase 3 · Lead
2031–2033
- Category leadership
- Premium mix & margin
- Platform & ecosystem
Board decisions & asks
§1.4 · p.14 →- Approve $46M capacity & capability investment
- Greenlight bolt-on M&A in Treatment Type
- Authorise North America expansion plan
- Fund R&D program for Diagnosis Method leadership
Risk watchlist (RAG)
§9 · p.180 →- Demand / macro slowdownOn track
- Competitive share lossAhead
- Input-cost & supply riskOn track
- Regulatory / policy changeBehind
- Execution & talentAt risk
Sales deck · value proposition
Win the Down Syndrome Diagnosis and Treatment Market conversation — a $3.45B market you can size, segment and defend in minutes.
Who buys (target personas)
§1.1 · p.4 →Product / BU leader
Head of Diagnosis Method
Goal Grow share in Diagnosis Method
Pain Blind spots on demand, pricing & competitors.
Regional GM
North America lead
Goal Prioritise the right markets
Pain No granular, country-level view of the market.
M&A / strategy
Strategy & Corp Dev
Goal Find where to invest or acquire
Pain Slow, inconsistent third-party research.
From pain to solution
§1.2 · p.6 →The business case (ROI)
Fig. 2 · p.9 →Why buyers trust it (proof points)
§1.3 · p.12 →Coverage includes
Objection handling
§1.4 · p.14 →“We already have market data.”
This triangulates 600K+ sources into one current, defensible view — not another silo.
“How do we know it’s accurate?”
Analyst-reviewed, and every figure is source-cited and traceable to its origin.
“It’s not in the budget.”
A fraction of a single analyst-day — and it pays back on the first decision it informs.
“We need it tailored to us.”
Choose the chapters, regions and companies before you build — you only pay for scope.
What you get (packages)
§1.5 · p.16 →Report
- Full multi-chapter report
- Market size, share & forecast
- Segment & regional breakdowns
- PDF + editable Excel + PPT
Report + Add-ons
- Everything in Report
- Interactive Visualizer
- Competitive benchmarking
- Investor / board / sales decks
Enterprise
- Multiple reports & markets
- Team seats & sharing
- Analyst support & custom scope
- API / data-feed options
Almost there
Access your Down Syndrome Diagnosis and Treatment Market report
Sign in to unlock the full report - it’s compiled live and ready in minutes.
Your report is ready to access
Down Syndrome Diagnosis and Treatment Market Report is ready
Verify your email to unlock it. We sent a 6-digit code to your inbox.
That code is invalid or expired. Please try again.
Trusted by strategy, finance & consulting teams
Related Reports
Healthcare and Pharmaceuticals · scroll →Isobutyl Chlorocarbonate Market
Market size, share, segmentation and regional forecast.
$3.4B market · 2025 base year
View reportHigh Barrier Packaging Films for Pharmaceuticals Market
Market size, share, segmentation and regional forecast.
$2.0B market · 2025 base year
View reportHexamethylenetetramine Market
Market size, share, segmentation and regional forecast.
$984M market · 2025 base year
View reportIndustrial Agar Market
Market size, share, segmentation and regional forecast.
$4.4B market · 2025 base year
View reportGlass Tubing & Rods Market
Market size, share, segmentation and regional forecast.
$5.2B market · 2025 base year
View reportGamma Linolenic Acid(GLA) Market
Market size, share, segmentation and regional forecast.
$2.6B market · 2025 base year
View reportDoula Care Service Market
Market size, share, segmentation and regional forecast.
$471M market · 2025 base year
View reportGanoderic Acid Market
Market size, share, segmentation and regional forecast.
$981M market · 2025 base year
View reportDoula And Birth Coaching Services Market
Market size, share, segmentation and regional forecast.
$3.4B market · 2025 base year
View reportFluoride Materials Market
Market size, share, segmentation and regional forecast.
$321M market · 2025 base year
View reportExcimer and Femtosecond Ophthalmic Lasers Market
Market size, share, segmentation and regional forecast.
$801M market · 2025 base year
View reportGalactosidase Market
Market size, share, segmentation and regional forecast.
$4.7B market · 2025 base year
View reportThe showdown
Custom-built vs. off-the-shelf
Scroll to watch them go head-to-head
- Tailored to your exact scope
- Delivered in minutes
- Live, always-current data
- Fully editable data (XLSX)
- You choose the companies
- Source-cited & traceable
- Generic, one-size template
- Waits 2–5 days
- A fixed snapshot in time
- Locked, flat PDF
- Preset company list
- Opaque sourcing
Customer Testimonials
Proof from industry leaders who rely on us
These stories come from the executives who depend on VMR’s intelligence for market entry, expansion, assessment, and planning. Their outcomes and experiences reflect our commitment to clarity.
In their words
Watch clients tell their story
How VMR helped University of Limerick with Anesthesia Monitoring Devices
How VMR helps brands expand into Africa & emerging markets
Unlock your GTM strategy: an Elsewedy Electric success story
Beyond sales data: layering NielsenIQ data to support strategy
How VMR became the trusted partner for United Alloy